Tough game that I’m proud of my boys for gutting out the win. Special regular season, setting school record for wins in a ...

Open Door’s Briella Bendik, Strongsville’s Sidney Butera, Keystone’s Madyson Sokolowski and Brush’s Tatiana Mason top the ...

Ryder Gorham led the squad with 29 points, 12 assists and five rebounds. The game prior, Gorham broke the school's ...

Eli Lilly’s stock closed 10.3% higher on Wednesday after the drug giant reported triple-digit growth of Zepbound and Mounjaro, its game-changing weight-loss and Type 2 diabetes drugs. That’s the third ...

Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news like ...

Eli Lilly is rated SELL due to lofty valuation, despite extraordinary execution and recent market leadership in GLP-1 and obesity drugs. LLY's current $950B market cap implies sustained 25% annual ...

After Novo Nordisk projected yesterday that its revenue could decline by as much as 13% in 2026, its share price has plummeted by 20%. Because the Danish company attributed much of the shortfall to ...

As Eli Lilly awaits an FDA approval decision for its oral GLP-1 orforglipron, the pharma has discarded three clinical-stage drugs, including a gene therapy from its $1 billion acquisition of Prevail ...

Eli Lilly posted fourth-quarter earnings and revenue and 2026 guidance that blew past estimates, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soars. The ...

Profit and revenue forecasts for 2026 well above Street view Lilly's Q4 profit and revenue exceed expectations Lilly's obesity drug Zepbound boosts sales despite price cuts Lilly's orforglipron pill ...

Eli Lilly & Co. provided an upbeat sales forecast for the year Wednesday as strong demand for its weight loss drug cemented its position at the top of the obesity market. The guidance was a sharp ...